FDA Approves First Generic of Popular Blood Thinner
FDA Approves First Generic of Popular Blood Thinner
The first generic versions of the powerful blood thinner Eliquis (apixaban) were approved by the U.S. Food and Drug Administration on Monday.
“Today’s approvals of the first generics of apixaban are an example of how the FDA’s generic drug program improves access to lower-cost, safe and high-quality medicines,” Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said in an agency news release.
“These approvals mark the first generic approvals of a direct oral anticoagulant,” Woodcock noted. “Direct oral anticoagulants [blood thinners] do not require repeated blood testing.”
The two types of generic tablets were approved to reduce the risk of stroke and systemic clotting in the lungs of patients with non-valvular atrial fibrillation and for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (lung clots), in patients who have had hip or knee replacement surgery.
Atrial fibrillation is a heart rhythm disorder that raises the risk of blood clots. It is estimated that between almost 3 and 6 million Americans have atrial fibrillation, according to the U.S. Centers for Disease Control and Prevention. Many of these individuals use anticoagulants or anti-clotting drugs to reduce that risk, the FDA noted.
There is an increased risk of blood clots forming inside a blood vessel, or strokes, if a patient stops using apixaban too early, the agency said.
Patients with prosthetic heart valves should not take apixaban nor should patients with atrial fibrillation that is caused by a heart valve problem. As with other approved anti-clotting drugs, bleeding, including life-threatening and fatal bleeding, is the most serious risk with apixaban.
The generic apixaban approvals were granted to Micro Labs Limited and Mylan Pharmaceuticals Inc.
Source: healthday
About Taj Pharma
Taj Pharmaceuticals is the global leader in generics and one of the India’s top ten pharmaceutical companies. Taj Pharma India play a leading role in therapeutic areas such as cancer, virology and transplantation. The combined strengths of Taj Pharma generics and pharmaceuticals businesses, coupled with expertise in the emerging genetic sciences, equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients’ needs. Taj Pharmaceutical’s products and services address the entire healthcare spectrum, from screening for genetic risk factors, to preventing, diagnosing and treating disease, and monitoring the treatment response.
Taj Pharma India delivers a unique contribution to better healthcare. Taj Pharma India aim to reduce suffering and improve health and quality of life of people all around the world. At Taj Pharmaceuticals, Taj Pharma India have pursued this mission with patience, dedication, imagination and skill, for over a century. Taj Pharma vision is to develop targeted medicines and diagnostic tools that combine to offer patients, physicians and payers better, safer, more cost-effective healthcare.
Once again, welcome to Taj Pharmaceuticals, a great company that is translating a great vision into reality — We Innovate Healthcare.
Tags: Taj Pharma, Taj Pharmaceutical, Taj Pharma Mumbai, Taj Pharma India, Mumbai Based Taj Pharma, Taj Pharma News, Taj Pharma Medicine, Taj Pharma Latest Breaking News, Taj Pharma Pictures, Taj Pharma Videos, Taj Pharma Special Reports from The Pharma Times, Taj Pharma Medicine Blogs, Taj Pharma Comments and Archive